We develop therapeutic agents for the treatment of cancer based on the invention of Dr Shisong Jiang – Recombinant Overlapping Peptides (ROP)
What We Do
These agents are an exciting new way to deliver immunotherapy which is now a major focus in the treatment of cancer, making it easier to deliver, more effective and much more economical. Immunotherapy is effective by activating the immune system to attack tumours directly thus reducing the need for invasive treatments such as chemo and radiotherapy.
Oxford Vacmedix is looking for a large pharmaceutical firm to codevelop its ROP technology, a suitable CMO for GMP-level production for its preclinical/phase 1 vaccine trials in Europe, and firms that can sequence tumor mutations against which it can design personalized vaccines (neoantigens).
The company is also interested in collaborating with organizations that can provide checkpoint inhibitors suitable for combination with ROP vaccines.*
* Text courtesy of BioPharma Dealmakers, September 2017
Dr Shisong Jiang (PhD)
Chief Scientific Officer and Founder
Dr Jiang is a globally renowned immunologist from Oxford University with previous experience at the Dana Farber Cancer Institute in the USA.
He has the longest experience of researching Overlapping Peptides as vaccines and has led all the development work vested in the company.
He is therefore extremely well placed to progress the technology with the current candidates and the future opportunities in the pipeline.
William Finch (MA, C.Dip AF)
Chief Executive Officer
After graduating from Oxford in Biochemistry William has over 34 years experience in the Biotech sector with a particular focus on leading SMEs.
Previous companies include R&D Systems, Amersham International, British Biotech and Beckman Coulter alongside small start-ups following outsourcing strategies where relevant.
Dr Anthony Coombs (DPhil)
Tony has a DPhil from Oxford in Chemistry and 30 years commercial experience in pharmaceutical development including work in Astra Zeneca Oncology, at MerckSerono and as CEO of Vifor Pharma.
He led the commercial development of Iressa for lung cancer and has wide experience working with oncology start-up companies, in Board roles and as a consultant. Tony also has roles in the NHS and as a Trustee for a lung cancer charity.
Louisa qualified with PwC in 2003 moving to experience as Financial Controller and Management Accounting with Innovision Research & Technology and Thames Water respectively.
She now provides independent accounting and company secretarial support to small businesses.
Dr Wenshu Lu (PhD)
Changzhou (CBI) Director of R&D
Dr. Lu received her PhD from Cologne (Germany) with postdoc training at University of Durham (UK) before joining Dr Jiang’s team in Oxford as an immunologist.
In 2015, Dr. Lu joined shanghai JW Inflinix company in China as R&D director leading the R&D work of diagnosis and therapies in inflammation diseases.
Now she leads the R&D team in CBI developing the pipelines in immuno-therapies in cancer and the TB diagnostic.
If you want to have a quick chat, or leave us some feedback,
you can contact us using any of the methods below